WC
CBMG

Wexford Capital’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Wexford Capital’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-13,700
Closed -$514K – 109
2015
Q2 		$514K Hold
13,700
– – 0.14% 58
2015
Q1 		$431K Buy
+13,700
New +$370K 0.13% 56

Other funds holding CBMG

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return

Wexford Capital's CBMG Position: Q3 2015 in Review

Wexford Capital sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q3 2015, closing a stake of 13,700 shares — an estimated $514K sold.

Wexford Capital first reported a position in CBMG in Q1 2015 and held it in 2 quarters. The position peaked at $514K in Q2 2015. 38 funds tracked by Wall St. Rank hold CBMG as of Q3 2015.

  • Wexford Capital reported no remaining Cellular Biomedicine Group, Inc. position as of Q3 2015 after selling out during the quarter.
  • Wexford Capital sold 13,700 Cellular Biomedicine Group, Inc. shares in Q3 2015, an estimated $514K.
  • Wexford Capital first reported a position in Cellular Biomedicine Group, Inc. in Q1 2015 and held it in 2 quarters.
  • Wexford Capital's Cellular Biomedicine Group, Inc. position peaked at $514K in Q2 2015.
  • 38 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q3 2015.

Based on Wexford Capital's 13F filing for Q3 2015, filed 13 Nov 2015.